Trial Profile
Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions
- Acronyms SIMM
- 06 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 06 Apr 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 25 Sep 2015 Planned End Date changed from 1 Aug 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.